PharmiWeb.com - Global Pharma News & Resources
21-Jul-2020

Coronavirus (COVID-19) Update: Daily Roundup

SILVER SPRING, Md., July 21, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today continued to take action in the ongoing response to the COVID-19 pandemic:

  • A new FDA Voices, tilted FDA's Ongoing Work to Support and Advance COVID-19 Diagnostic Test Accuracy and Availability, describes how FDA has been proactive and supportive of test development by all comers — including laboratories, and large and small commercial manufacturers — to speed development and to quickly authorize tests that the science supports. The agency engaged with the lab and commercial manufacturer communities even before any cases of COVID-19 were diagnosed in the United States, working with more than 500 developers since January. FDA has been working around the clock to issue more than 180 Emergency Use Authorizations (EUAs) tests, including molecular, serology, antigen, and tests with at-home-specimen-collection indications.
  • Testing updates:
    • To date, the FDA has currently authorized 186 tests under EUAs; these include 153 molecular tests, 31 antibody tests, and 2 antigen tests.

Additional Resources:

Media Contact: Lee.Herring@fda.hhs.gov
Consumer Inquiries
: 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/coronavirus-covid-19-update-daily-roundup-301097531.html

SOURCE U.S. Food and Drug Administration

Coronavirus (COVID-19) Update: Daily Roundup

Editor Details

Last Updated: 21-Jul-2020